DPH Stock Overview
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 4/6 |
Past Performance | 0/6 |
Financial Health | 1/6 |
Dividends | 0/6 |
Dechra Pharmaceuticals PLC Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | UK£38.66 |
52 Week High | UK£41.46 |
52 Week Low | UK£24.73 |
Beta | 0.78 |
1 Month Change | 0.68% |
3 Month Change | 1.84% |
1 Year Change | 32.40% |
3 Year Change | 5.57% |
5 Year Change | 60.15% |
Change since IPO | 2,828.79% |
Recent News & Updates
Recent updates
Dechra Pharmaceuticals (LON:DPH) Takes On Some Risk With Its Use Of Debt
May 31A Look At The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Mar 28We Think Dechra Pharmaceuticals (LON:DPH) Is Taking Some Risk With Its Debt
Mar 02Dechra Pharmaceuticals' (LON:DPH) Dividend Will Be Increased To £0.125
Mar 02Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Dec 09Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To £0.3289
Oct 06Dechra Pharmaceuticals (LON:DPH) Is Paying Out A Larger Dividend Than Last Year
Sep 22Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At £0.3289
Sep 08Estimating The Intrinsic Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Aug 18Do Dechra Pharmaceuticals' (LON:DPH) Earnings Warrant Your Attention?
Aug 02These 4 Measures Indicate That Dechra Pharmaceuticals (LON:DPH) Is Using Debt Reasonably Well
Jun 10Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
May 08Do Dechra Pharmaceuticals's (LON:DPH) Earnings Warrant Your Attention?
Apr 22Dechra Pharmaceuticals (LON:DPH) Is Increasing Its Dividend To UK£0.12
Feb 23Is Dechra Pharmaceuticals PLC (LON:DPH) Expensive For A Reason? A Look At Its Intrinsic Value
Jan 29Is Now The Time To Put Dechra Pharmaceuticals (LON:DPH) On Your Watchlist?
Jan 11Here's Why Dechra Pharmaceuticals (LON:DPH) Can Manage Its Debt Responsibly
Dec 04It Looks Like Shareholders Would Probably Approve Dechra Pharmaceuticals PLC's (LON:DPH) CEO Compensation Package
Oct 15Dechra Pharmaceuticals' (LON:DPH) Upcoming Dividend Will Be Larger Than Last Year's
Sep 25Dechra Pharmaceuticals (LON:DPH) Will Pay A Larger Dividend Than Last Year At UK£0.29
Sep 11With EPS Growth And More, Dechra Pharmaceuticals (LON:DPH) Is Interesting
Sep 08Is Dechra Pharmaceuticals PLC (LON:DPH) Worth UK£43.4 Based On Its Intrinsic Value?
Jun 17Is Dechra Pharmaceuticals PLC (LON:DPH) A Smart Choice For Dividend Investors?
Apr 09Dechra Pharmaceuticals (LON:DPH) Has A Pretty Healthy Balance Sheet
Mar 05Are Dechra Pharmaceuticals' (LON:DPH) Statutory Earnings A Good Reflection Of Its Earnings Potential?
Feb 17Dechra Pharmaceuticals PLC (LON:DPH) Is Going Strong But Fundamentals Appear To Be Mixed : Is There A Clear Direction For The Stock?
Feb 02Did You Participate In Any Of Dechra Pharmaceuticals' (LON:DPH) Fantastic 268% Return ?
Jan 18Calculating The Fair Value Of Dechra Pharmaceuticals PLC (LON:DPH)
Jan 03Shareholder Returns
DPH | GB Pharmaceuticals | GB Market | |
---|---|---|---|
7D | 0.2% | -1.2% | -0.7% |
1Y | 32.4% | -5.0% | -1.8% |
Return vs Industry: DPH exceeded the UK Pharmaceuticals industry which returned -2.4% over the past year.
Return vs Market: DPH exceeded the UK Market which returned -6.7% over the past year.
Price Volatility
DPH volatility | |
---|---|
DPH Average Weekly Movement | 0.5% |
Pharmaceuticals Industry Average Movement | 8.7% |
Market Average Movement | 4.8% |
10% most volatile stocks in GB Market | 11.5% |
10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: DPH has not had significant price volatility in the past 3 months.
Volatility Over Time: DPH's weekly volatility has decreased from 6% to 0% over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1997 | 2,457 | Ian Page | www.dechra.com |
Dechra Pharmaceuticals PLC develops, manufactures, regulates, markets, and sells veterinary pharmaceuticals and related products for veterinarians. It operates through three segments: European Pharmaceuticals, North American Pharmaceuticals, and Pharmaceuticals. The company offers various endocrinology, dermatology, analgesia and anesthesia, cardiovascular, internal medicine, and nutrition products supporting cats and dogs with various therapeutic conditions, such as allergies, obesity, heart, and kidney diseases.
Dechra Pharmaceuticals PLC Fundamentals Summary
DPH fundamental statistics | |
---|---|
Market cap | UK£4.40b |
Earnings (TTM) | -UK£27.90m |
Revenue (TTM) | UK£761.50m |
5.8x
P/S Ratio-157.8x
P/E RatioIs DPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
DPH income statement (TTM) | |
---|---|
Revenue | UK£761.50m |
Cost of Revenue | UK£331.90m |
Gross Profit | UK£429.60m |
Other Expenses | UK£457.50m |
Earnings | -UK£27.90m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
Earnings per share (EPS) | -0.24 |
Gross Margin | 56.42% |
Net Profit Margin | -3.66% |
Debt/Equity Ratio | 64.6% |
How did DPH perform over the long term?
See historical performance and comparison